News|Videos|November 27, 2023
EGFR Exon 20 Insertion NSCLC: A Comprehensive Overview
Experts discuss the rapidly evolving treatment landscape for EGFR exon 20 insertion lung cancer, highlighting recent advancements in therapies, clinical trial results, and the quest for first-line treatment options, providing valuable insights into managing this unique patient population.
Advertisement
Episodes in this series
Advertisement
Related to this article
Medical oncologists, clinical pharmacists, and oncologic nurse practitioners share the presentation topics to look out for at WCLC 2026.
The interim 3-year OS rates were 71.2% with OST-HER2 vs 45.8% in historical controls in a phase 2b trial of fully resected, pulmonary metastatic osteosarcoma.
Partnering with subspecialities like ophthalmology and dermatology may be critical for nurse practitioners in lung cancer, according to Beth Sandy, CRNP.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
2
Japan Approves T-DXd Combo and Dato-DXd for First-Line Metastatic Breast Cancer
3
Fixed-Duration Combinations and MRD-Guided Therapy as Emerging Priorities in CLL
4
NCCN Guidelines Strengthen MRD Testing Recommendations in Multiple Myeloma
5